NIHR University College London Hospitals Biomedical Research Centre NIHR University College London Hospitals Biomedical Research Centre Report to UCLH Board Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 18/03/2013
The NIHR UCLH BRC • Renewed funding circa £100M for 5 years in April 2012; • Required a “refresh” of research strategy; • 17 themes reduced to 4 major research Programmes; • Cancer, • Neuroscience, • 3Is (Infection, Immunity, Inflammation), • Cardiometabolic; • New BRC Director; • 4 Programme Directors & Education/Training PD; • Operations manager for each programme; • BRC COO, also COO for R&D functions.
NIHR University College London Hospitals Biomedical Research Centre Changing face of the BRC • New BRC • Focussed on Experimental Medicine • Early phase human studies • CRF-based / Detailed clinical evaluation
NIHR University College London Hospitals Biomedical Research Centre Context for Change • NHS “Innovation for Health and Wealth” Agenda; • Major Government investment in UK Bioscience; • Key emphasis on leverage and wealth creation; • Industrial engagement – Pharma, MedTech, Biotech and SMEs; • Enterprise and Entrepreneurship from within; • Inward investment – Export Innovation • Innovation in Health Care; the “value proposition”
NIHR University College London Hospitals Biomedical Research Centre
NIHR University College London Hospitals Biomedical Research Centre Experimental Medicine and the Translational Pathway UCLH Innovation Office Accelerate translation UCLB / TRO / UCL Enterprise Clinical UCL/UCLH Trials UCLH UCLP BRC Reverse Translation Industrial Collaboration Sir Francis Crick Institute Cross BRC/BRU Collaboration Pan-London Collaboration Creating Health and Wealth CHAPTER eHealth
NIHR University College London Hospitals Biomedical Research Centre Change Process.. • Realignment of UCLH BRC funding towards Experimental Medicine; � Consultant PA’s, Non Consultant Staff, NHS Research Support Costs • Criteria for BRC support; � Research in the domain of experimental medicine � Research of high quality – REF returnable � Leverage of BRC support – “blue chip funding”, matched funding (faculty, NHS, industry, research councils, research charities, etc.) � Potential for Impact on Health and Wealth
NIHR University College London Hospitals Biomedical Research Centre BRC Budget Realignment “To build Capacity and deliver a step-change in World Class Experimental Medicine Research” The BRC budget review process should realign £20 million for Experimental Medicine (~£5M per annum)
NIHR University College London Hospitals Biomedical Research Centre BRC Budget Realignment In addition to Existing Substantial BRC funding for research and infrastructure that continues to be embedded in UCLH
NIHR University College London Hospitals Biomedical Research Centre What will success look like? Expand and Accelerate •Expansion of experimental medicine capability, capacity and delivery; Culture and Entrepreneurship •A vibrant culture of innovation, enterprise and entrepreneurship “hard- wired” into everything we do…and recognised and rewarded; Partnership and Industry •Attracting major inward investment by industry – Pharma, Med-tech, Cell therapies, Diagnostics, Imaging – real partnerships not simply transactional; Health and Wealth Creation •Improved health care efficiency and patient outcomes from fast-tracked innovation – wealth creation
BRC National Comparisons The most early phase human trials UCLH NIHR Analysis of Annual Reports 2011/12
Implications for UCLH • BRC funding is now robustly performance managed against delivery of the health and wealth agenda; • BRC budget needs to be strategically deployed; • Cost pressure (CSR) – need to be the best; • Failure to deliver would be catastrophic for UCLH
On the Horizon….. • Later Phase Clinical Trials – National Reconfiguration; • National NIHR Bioresource and Health Informatics initiatives – eHealth agenda; • Integrating and leveraging UCLP as gateway to scale.
Recommend
More recommend
